Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th
August 04 2021 - 8:00AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal
trial in Alzheimer's disease with topline data expected in the
fourth quarter of 2021 and a growing pipeline of therapeutics for
degenerative diseases, announced that Chris Lowe, the company’s
chief operating officer and chief financial officer, will
participate in a fireside chat at Canaccord Genuity' s 41st Annual
Growth Conference taking place virtually on Wednesday, August 11,
2021 at 3:00 p.m. ET / 12:00 p.m. PT.
A live webcast of the event will be accessible on the Investor
Calendar page under the News & Events heading of Cortexyme’s
investor website at ir.cortexyme.com. The webcast will be archived
at that location for 90 days.
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering upstream therapeutic
approaches designed to improve the lives of patients diagnosed with
Alzheimer’s and other degenerative diseases. The company is
advancing its disease-modifying pivotal GAIN Trial in mild to
moderate Alzheimer's disease with top-line data expected in the
fourth quarter of 2021, in addition to growing a proprietary
pipeline of first-in-class small molecule therapeutics for
Parkinson’s disease, periodontitis, and other diseases with high
unmet clinical need. Cortexyme’s lead program targets a specific,
infectious pathogen called P. gingivalis found in the brain and
other organs and tied to degeneration and inflammation in humans
and animal models. The company’s causation evidence for Alzheimer’s
disease and the mechanism of its novel therapeutic has been
independently replicated and confirmed by multiple laboratories
around the world, as well as published in peer-reviewed scientific
journals. To learn more about Cortexyme, visit www.cortexyme.com or
follow @Cortexyme on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210804005084/en/
Corporate Contact: Stacy Roughan Vice President,
Corporate Communications & Investor Relations Cortexyme, Inc.
ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024